엑셀세라퓨틱스, 복지부 '원부자재 국산화 사업' 선정…생산능력 확대

Excelserapeutics' selection as South Korea's first domestic raw materials localization program beneficiary addresses biopharmaceutical supply chain vulnerabilities while enabling 2.5x production expansion. The shift to automated large-scale manufacturing, supported by government funding, positions the company to capture surging global demand from CDMO and pharmaceutical partners. This demonstrates a scalable model for biotech firms to achieve domestic self-sufficiency while building global competitiveness.